Tissue Engineering And Nanotheranostics

b2815 Tissue Engineering and Nanotheranostics “9.61x6.69”

274 Tissue Engineering and Nanotheranostics

231. Greish K. Enhanced permeability and retention of macromolecular
     drugs in solid tumors: A royal gate for targeted anticancer nanomedi­
     cines. J. Drug Target. 15 , 457–464 (2007).


232. Jabr­Milane LS, van Vlerken LE, Yadav S, Amiji MM. Multi­functional
     nanocarriers to overcome tumor drug resistance. Cancer Treat. Rev.
     34 , 592–602 (2008).


233. Godin B, Tasciotti E, Liu X, Serda RE, Ferrari M. Multistage nanovec­
     tors: from concept to novel imaging contrast agents and therapeutics.
     Acc. Chem. Res. 44 , 979–989 (2011).


234. Ruoslahti E. Peptides as targeting elements and tissue penetration
     devices for nanoparticles. Adv. Mater. 24 , 3747–3756 (2012).


235. Wang Z, Yu Y, Dai W, Lu J, Cui J, Wu H, Yuan L, Zhang H, Wang X,
     Wang J, Zhang X, Zhang Q. The use of a tumor metastasis targeting
     peptide to deliver doxorubicin­containing liposomes to highly meta­
     static cancer. Biomaterials 33 , 8451–8460 (2012).


236. Mukherjee B. Nanosize drug delivery system. Curr. Pharm. Biotechnol.
     14 , 1221 (2013).


237. Beduneau A, Saulnier P, Benoit JP. Active targeting of brain tumors
     using nanocarriers. Biomaterials 28 , 4947–4967 (2007).


238. Gupta B, Torchilin VP. Monoclonal antibody 2C5­modified doxorubicin­
     loaded liposomes with significantly enhanced therapeutic activity against
     intracranial human brain U­87 MG tumor xenografts in nude mice.
     Cancer Immunol. Immunother 56 , 1215–1223 (2007).


239. Nie S, Xing Y, Kim GJ, Simons JW. Nanotechnology applications in
     cancer. Ann. Rev. Biomed. Eng. 9 , 257–288 (2007).


240. Ding B, Wu X, Fan W, Wu Z, Gao J, Zhang W, Ma L, Xiang W, Zhu
     Q, Liu J, Ding X, Gao S. Anti­DR5 monoclonal antibody­mediated
     DTIC­loaded nanoparticles combining chemotherapy and immuno­
     therapy for malignant melanoma: Target formulation development and
     in vitro anticancer activity. Int. J. Nanomed. 6 , 1991–2005 (2011).


241. Al­Ahmady ZS, Chaloin O, Kostarelos K. Monoclonal antibody­
     targeted, temperature­sensitive liposomes: In vivo tumor chemothera­
     peutics in combination with mild hyperthermia. J. Control. Rel. 196 ,
     332–343 (2014).


242. Maloney DG, Grillo­Lopez AJ, White CA, Bodkin D, Schilder RJ,
     Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, Wey K,
     Royston I, Davis T, Levy R. IDEC­C2B8 (Rituximab) anti­CD20
     monoclonal antibody therapy in patients with relapsed low­grade non­
     Hodgkin’s lymphoma. Blood 90 , 2188–2195 (1997).